AZD4573
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Peripheral T-cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Trial Timeline
Dec 15, 2021 → Feb 16, 2024
NCT ID
NCT05140382About AZD4573
AZD4573 is a phase 2 stage product being developed by AstraZeneca for Relapsed/Refractory Peripheral T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05140382. Target conditions include Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Peripheral T-cell Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05140382 | Phase 2 | Completed |
| NCT03263637 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Peripheral T-cell Lymphoma